C4X Discovery Holdings plc announced that it has received a milestone payment of $11 million from AstraZeneca triggered by preclinical progress of C4XD's NRF2 Activator programme. Under the terms of the licensing agreement announced in November 2022, C4XD received an initial $2 million upfront payment and is potentially entitled to receive up to $400 million in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales. AstraZeneca is developing C4XD's former NRF2 Activator programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | +27.32% | -.--% | +33.33% |
Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
Apr. 25 | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 37.99M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- C4XD Stock
- News C4X Discovery Holdings plc
- C4X Discovery Holdings plc Receives Milestone Payment of $11 Million from AstraZeneca